The Corporate Travel Management Ltd (ASX: CTD) share price is in focus after the company released an update highlighting delays to its FY25 and 1HFY26 financial statements and progress on UK customer remediation.

What did Corporate Travel Management report?

• FY25 and 1HFY26 financial statements are substantially advanced but still incomplete
• FY25 and 1HFY26 accounts now expected to be lodged in August 2026
• Estimated FY24 revenue restatement of $10–15 million in the ANZ region, mostly relating to prior years
• Impairment of Europe goodwill expected at GBP 92 million
• Further goodwill impairment expected in ANZ (AUD 77 million) and North America (USD 49 million)

What else do investors need to know?

Corporate Travel Management is focused on completing three key, interconnected activities: finalising financing to support UK remediation, executing agreements with affected UK customers, and completing outstanding financial reporting and audit procedures.

The UK remediation process is well advanced, with Corporate Travel Management in the final stages of negotiating staged refund arrangements with key customers. This remains subject to completion of the FY25 accounts and associated financing, with lenders engaged regarding these developments.

What did Corporate Travel Management management say?

Acting Group CEO Ana Pedersen said:

We recognise the delay is deeply frustrating for shareholders and acknowledge the uncertainty it has created.

We have made meaningful progress towards finalising CTM’s financial statements, UK customer remediation and financing workstreams.
As we move through the final stages, the remaining tasks are interdependent, and we are working through them carefully and with rigour, to ensure a thorough and appropriate outcome.

Importantly, the underlying business remains resilient, with strong customer retention and consistent quality service across our global operations.

What’s next for Corporate Travel Management?

The company now aims to complete and lodge its FY25 and 1HFY26 financial statements in August. Finalising agreements with lenders and impacted UK customers remains a top priority, alongside implementing the staged remediation refunds.

Management says the underlying operations continue to display resilience, and the company will provide further market updates as soon as the remaining processes are finalised.

View Original Announcement

The post Corporate Travel Management updates investors on delayed FY25 results and UK remediation appeared first on The Motley Fool Australia.

More reading

• Lendlease Group shares paused pending further announcement
• Worley flags FY26 earnings hit from Middle East delays and currency impact
• Pro Medicus signs Echo IQ deal to boost AI cardiology offering
• Ventia Services appoints new CEO in leadership succession
• A2 Milk declares $300 million special dividend after securing China approval

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Corporate Travel Management. The Motley Fool Australia has positions in and has recommended Corporate Travel Management. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Worley Ltd (ASX: WOR) share price is in focus after the company flagged a potential hit of up to $60 million to FY26 underlying EBITA from ongoing Middle East conflict disruptions, alongside a $50 million foreign currency translation impact expected in the same period.

What did Worley report?

• No cancellations of Middle East projects to date, but new project starts and awards continue to be delayed
• FY26 underlying EBITA impact now forecast up to $60 million (previously $30–$40 million)
• Additional $50 million estimated translation impact on FY26 underlying EBITA from stronger Australian dollar
• Update reflects increased uncertainty and extended conflict duration in the region

What else do investors need to know?

The Middle East conflict continues to disrupt the progress of Worley’s existing projects across the region, with customer delays on commencing and awarding new projects. While no contracts have been cancelled, ongoing delays are expected to weigh on upcoming financial performance.

Worley also advised that the stronger Australian dollar in the second half of FY26 will reduce the contribution from overseas earnings when translated back into Australian dollars, compounding the previously announced operational impacts. The estimate of foreign currency translation effects remains subject to further exchange rate movements throughout the year.

What’s next for Worley?

Looking ahead, Worley continues to monitor the evolving geopolitical situation. While recent diplomatic developments in the Middle East show some promise, the company remains cautious, acknowledging ongoing uncertainty regarding project timing and regional stability. Management is actively supporting customers and staff in affected regions and adapting resource planning and contract strategies to manage risks.

Worley’s broader strategy focuses on maintaining operational resilience and leveraging its global footprint through diversified service offerings. The company says it is committed to supporting customers as they navigate current disruptions and transition towards more sustainable solutions in the longer term.

Worley share price snapshot

Over the past 12 months, Worley shares have declined 6%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Worley flags FY26 earnings hit from Middle East delays and currency impact appeared first on The Motley Fool Australia.

More reading

• Lendlease Group shares paused pending further announcement
• Corporate Travel Management updates investors on delayed FY25 results and UK remediation
• Pro Medicus signs Echo IQ deal to boost AI cardiology offering
• Ventia Services appoints new CEO in leadership succession
• A2 Milk declares $300 million special dividend after securing China approval

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Telix Pharmaceuticals Ltd (ASX: TLX) shares have been gaining momentum in 2026.

The ASX healthcare share is up 18% over the past month and 40% since the start of the year. While the stock remains down 36% over the past 12 months, investors have become increasingly optimistic about the company’s prospects.

That renewed confidence appears to extend well beyond retail investors.

According to an ASX filing released today, global investment giant Vanguard Group recently acquired 17.7 million Telix shares, lifting its voting power to 5.2%.

The sizeable position suggests Vanguard sees value in the healthcare company despite its strong recent rally.

Why are Telix shares attracting attention?

Telix specialises in radiopharmaceuticals, a fast-growing area of healthcare that combines targeted imaging and therapeutic technologies to help diagnose and treat diseases such as cancer.

The company has built expertise across research, development, manufacturing, and commercialisation, creating significant barriers to entry for potential competitors.

Developing radiopharmaceutical products requires specialised facilities, regulatory approvals, and distribution capabilities that are difficult and expensive to replicate.

That gives Telix shares a competitive advantage in a market expected to experience strong long-term growth.

Positive news flow continues

Investor sentiment has improved considerably in recent months following a series of encouraging announcements.

In late February, Telix secured a key regulatory approval filing in Europe, an important milestone as the company expands its commercial footprint internationally.

Momentum continued in April when the company announced that the US Food and Drug Administration had accepted its New Drug Application for TLX101-Px (Pixclara®).

The FDA’s acceptance represents a significant step towards potential commercialisation and broadened the company’s pipeline opportunities.

These developments have helped rebuild investor confidence following a challenging period for Telix shares.

Strong financial performance

The company’s financial results have also strengthened the investment case.

In April, Telix reported first-quarter 2026 group revenue of US$230 million. That represented an 11% increase on the previous quarter and a 23.7% rise compared to the prior corresponding period.

Management of Telix shares continues to guide for strong growth, supported by its expanding Precision Medicine business and a growing portfolio of radiopharmaceutical products.

Importantly, the company continues to invest heavily in research and development, helping advance multiple late-stage programs and future growth opportunities.

Vanguard and analysts see further upside

Vanguard is not alone in its optimism.

According to TradingView data, the majority of analysts covering the ASX healthcare share currently rate it as a strong buy.

The most bullish price target stands at $31.64 per share, implying potential upside of approximately 101% from current levels.

Meanwhile, Morgans has a $24.33 price target on the stock, suggesting upside of around 55%.

While no investment is without risk, Vanguard’s decision to build a sizeable position suggests one of the world’s largest fund managers believes Telix’s growth story is far from over.

The post Why this top investor is snapping up millions of Telix shares appeared first on The Motley Fool Australia.

More reading

• 3 reasons to buy this recovering ASX healthcare share
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• 2 ASX growth shares that could double your money
• Here are the 10 most shorted ASX shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.